Jeffrey M. Axten

Discovery of 7-Methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1<i>H</i>-indol-5-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (GSK2606414), a Potent and Selective First-in-Class Inhibitor of Protein Kinase R (PKR)-like Endoplasmic Reticulum Kinase (PERK)

Jeffrey M. Axten, Jesús R. Medina, Yanhong Feng et al. · Journal of Medicinal Chemistry · 2012 · 601 citations · Full text

Chemoprevention Strategy, Chemical Biology, Pharmaceutical Chemistry +24

Oral Treatment Targeting the Unfolded Protein Response Prevents Neurodegeneration and Clinical Disease in Prion-Infected Mice

Julie A. Moreno, Mark Halliday, Colin Molloy et al. · Science Translational Medicine · 2013 · 566 citations

Creutzfeldt-jakob Disease, Immunology, Cell Death +18

Characterization of a Novel PERK Kinase Inhibitor with Antitumor and Antiangiogenic Activity

Charity Atkins, Qi Liu, Elisabeth A. Minthorn et al. · Cancer Research · 2013 · 426 citations

Tumor Biology, Signaling Pathway, Upr Signaling +21

Discovery of GSK2656157: An Optimized PERK Inhibitor Selected for Preclinical Development

Jeffrey M. Axten, Stuart P. Romeril, Arthur Y. L. Shu et al. · ACS Medicinal Chemistry Letters · 2013 · 224 citations · Full text

Drug Discovery Program, Tumor Biology, Physical Properties +18

Targeting PERK signaling with the small molecule GSK2606414 prevents neurodegeneration in a model of Parkinson's disease

Gabriela Mercado, Valentina Castillo, Paulina Soto et al. · Neurobiology of Disease · 2018 · 166 citations · Full text

Neurodegenerative Diseases, Signal Transduction, Autophagy +9